Detalles de la búsqueda
1.
Ovarian cancer mutational processes drive site-specific immune evasion.
Nature
; 612(7941): 778-786, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36517593
2.
Trends in specific procedures performed at the time of cytoreduction for ovarian cancer: Is interval debulking surgery truly less radical? A Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol
; 187: 80-84, 2024 May 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38735143
3.
Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer.
Gynecol Oncol
; 186: 104-109, 2024 Apr 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38640773
4.
Regionalizing ovarian cancer cytoreduction to high-volume centers and the impact on patient travel in New York State.
Gynecol Oncol
; 182: 141-147, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38262237
5.
ARIA II: a randomized controlled trial of near-infrared Angiography during RectosIgmoid resection and Anastomosis in women with ovarian cancer.
Int J Gynecol Cancer
; 2024 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38514101
6.
Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol
; 169: 118-124, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36565685
7.
Sentinel lymph node mapping in patients with endometrial hyperplasia: A practice to preserve or abandon?
Gynecol Oncol
; 168: 1-7, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36334496
8.
Impact of postoperative morbidity on outcomes in patients with advanced epithelial ovarian cancer undergoing intestinal surgery at the time of primary or interval cytoreductive surgery: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol
; 179: 169-179, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37992548
9.
Ten-year conditional probability of survival for patients with ovarian cancer: A new metric tailored to Long-term survivors.
Gynecol Oncol
; 169: 85-90, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36521353
10.
Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial.
Gynecol Oncol
; 171: 23-30, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36804618
11.
Patient-reported symptoms after minimally invasive hysterectomy and association with postoperative complications.
Gynecol Oncol
; 175: 163-168, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37390597
12.
Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol
; 176: 69-75, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37454565
13.
Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: Going to the next level - A Memorial Sloan Kettering Cancer Center study.
Gynecol Oncol
; 170: 46-53, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36621269
14.
Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management.
Gynecol Oncol
; 170: 93-101, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36669327
15.
Safety and feasibility of therapeutic anticoagulation for newly diagnosed venous thromboembolism in women who undergo neoadjuvant chemotherapy for advanced ovarian cancer.
Int J Gynecol Cancer
; 2023 Dec 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38088180
16.
Enhanced PAtient Clinical Streamlining (EPACS): Quality Initiative to Improve Healthcare for New Surgical Outpatient Visits.
Ann Surg Oncol
; 29(3): 1789-1796, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34984565
17.
A modern-day experience with Brunschwig's operation: Outcomes associated with pelvic exenteration.
Gynecol Oncol
; 167(2): 277-282, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36064678
18.
Risk factors for financial toxicity in patients with gynecologic cancer.
Am J Obstet Gynecol
; 226(6): 817.e1-817.e9, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34902319
19.
Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
Gynecol Oncol
; 162(2): 345-352, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34045053
20.
Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer.
Gynecol Oncol
; 161(3): 687-692, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33773807